Eprex Use In Pregnancy & Lactation

Pregnancy: In animal studies, Epoetin alfa has been shown to decrease fetal body weight, delay ossification and increase fetal mortality when given in weekly doses of approximately 20 times the recommended human weekly dose. These changes are interpreted as being secondary to decreased maternal body weight gain.
There are no adequate and well-controlled studies in pregnant women.
Eprex should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (see Pharmacology: Toxicology: Non-Clinical Information: Reproductive Toxicology under Actions).
Breast-feeding: Erythropoietin is present in human milk. However, it is not known whether Eprex is distributed into human milk. Eprex should be used with caution in nursing women.
In pregnant or lactating surgical patients participating in an autologous blood predonation program, the use of Eprex is not recommended.
Fertility: The effect of Eprex on human fertility has not been studied (see Pharmacology: Toxicology: Non-Clinical Information: Reproductive Toxicology under Actions).